Videos

Learn how emerging advanced scans outpace CT and bone scans in finding micrometastatic prostate cancer and shaping treatment teamwork.

C. Shawn West, MD, provides an overview of the pre-MIST era in BPH management, highlighting the reliance on invasive surgical approaches and the clinical and patient-centered limitations that drove innovation.

Suction-enabled ureteroscopy platforms and artificial intelligence (AI)-driven prediction and planning tools represent 2 parallel frontiers in kidney stone management, with active fragment evacuation already in clinical use and AI poised to reshape preoperative planning, patient selection, and intraoperative guidance.

In this segment, Dr. Charles J. Ryan invites the panel to discuss how clinicians interpret clinical trial results in the context of real world patient populations with metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan leads a panel discussion with Dr. Alan H. Bryce, Dr. Murilo De Almeida Luz, and Dr. Jayram on key clinical considerations that influence treatment selection when intensifying therapy for metastatic castration sensitive prostate cancer (mCSPC).

David R. Wise, MD, PhD, discusses the potential for pasritamig combined with docetaxel to improve outcomes in patients with mCRPC.

Robert Flavell, MD, PhD, and Anil P. Bidkar, PhD, discuss the synergistic potential of CD46-directed alpha radiation and ADC therapy combination.

Akanksha Mehta, MD, MS, discusses AUA guideline recommendations for performing post-vasectomy semen analysis.

Neha Vapiwala, MD, FASTRO, discusses the integration of radiation therapy with systemic treatment intensification across different stages of localized and locally advanced prostate cancer.

Experts discuss the implications of the FDA’s potential pathway to expand testosterone replacement therapy labeling for low libido in men with idiopathic hypogonadism.

In the final episode, ‘Advice for Integrating PSMA PET Imaging in Advanced Prostate Cancer,’ the panelists share practical advice for incorporating PSMA PET into prostate cancer clinics and workflows.

Kyle M. Rose, MD, discusses key considerations for optimizing the timing and sequencing of inguinal and pelvic lymph node dissection.

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss how clinicians interpret data from pivotal phase 3 clinical trials evaluating androgen receptor pathway inhibitors used in combination therapy for metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan invites Dr. Jayram and Dr. Alan H. Bryce to discuss how potential central nervous system effects influence treatment selection in metastatic castration sensitive prostate cancer (mCSPC).

Akanksha Mehta, MD, MS, discusses updated recommendations from the 2026 AUA Vasectomy Guideline on vas isolation and occlusion techniques.

Fred Saad, MD, FRCS, discusses findings from a post hoc analysis of the phase 3 ARANOTE trial.

Medtronic's Touch Surgery enterprise platform, integrated with the Hugo robotic system, offers AI-driven case segmentation, real-time anatomic overlay, and two-way telementoring capabilities that James R. Porter, MD, describes as the most robust digital offering currently available on a robotic surgery platform.

Meri-Margaret Deoudes discusses findings from BCAN's New Faces of Bladder Cancer Report.

Daniel J. George, MD, highlights patient-reported outcomes and tolerability findings from the phase 3 CAPItello-281 trial, evaluating the addition of capivasertib to abiraterone in patients with PTEN-deficient de novo mHSPC.

Minas P. Economides, MD, discusses the evolving role of biomarkers such as KIM-1 in refining risk stratification and highlighted emerging innovations that may reshape how kidney cancer is both imaged and therapeutically targeted.

In this video, Jennifer Miles-Thomas, MD, recaps a SUFU 2026 discussion on leveraging surgeon–APP collaborations in urology.

In this episode, ‘Clinical Reliability of PSMA PET in Advanced Prostate Cancer,’ expert faculty examine the real-world reliability of PSMA PET imaging in evaluating tumor burden and disease extent in advanced prostate cancer.

In a controlled silicone kidney model, CVAC 2.0 outperformed a FANS sheath system for moderate-to-larger stone fragments across clearance efficiency, residual volume, and surgeon ergonomics, though the authors note the model was designed to isolate aspiration mechanics rather than replicate full clinical procedures.

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss the importance of evaluating drug drug interaction profiles when selecting androgen receptor pathway inhibitors for patients with metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce to discuss how long term tolerability influences the selection of androgen receptor pathway inhibitors for patients with metastatic castration sensitive prostate cancer (mCSPC).

Akanksha Mehta, MD, MS, highlights key recommendations on pre-vasectomy counseling from the American Urological Association’s 2026 Vasectomy Guideline.

Stacy Loeb, MD, MSc, discusses emerging data on microplastics and prostate cancer and highlights practical steps to reduce plastic exposure.

In this video, Gordon A. Brown, DO, FACOS, offers perspective on integrating PTEN testing and AKT inhibition into evolving biomarker-driven treatment strategies for mHSPC.